drugset / Trial / NCT06825416

A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

NCT06825416

Phase 3 Completed 1166 enrolled Beijing Suncadia Pharmaceuticals Co., Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty.

Timeline

Start
2025-03-16
Primary completion
2026-02-15
Completion
2026-04-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified
Subject SHR-2004 Monoclonal antibody

Indications

No indication recorded.